LightPath Technologies GAAP EPS of -$0.06 misses by $0.01, revenue of $8.6M beats by $0.3M Seaking Alpha Seeking Alpha / Seaking Alpha 8 hours ago 1 Views Read more
Seaking Alpha Ultima Markets Wins Two Prestigious Awards at Global Forex Awards--Retail 2024! Seeking Alpha / Seaking Alpha - 1 hour ago
Seaking Alpha Gen.G Esports Announces Partnership with Descente to Launch the Worlds 2024 Uniform Seeking Alpha / Seaking Alpha - 1 hour ago
Seaking Alpha Trinity Capital Inc. Increases its Credit Facility to $510 Million Seeking Alpha / Seaking Alpha - 1 hour ago
Seaking Alpha FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER Seeking Alpha / Seaking Alpha - 1 hour ago
Seaking Alpha SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, FYBR, GATO, SGRP on Behalf of Shareholders Seeking Alpha / Seaking Alpha - 1 hour ago
Seaking Alpha RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer Seeking Alpha / Seaking Alpha - 2 hours ago
Comments